Search Results - "Nikkho, Sylvia M"

Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC by Becker-Pelster, Eva M, Hahn, Michael G, Delbeck, Martina, Dietz, Lisa, Hüser, Jörg, Kopf, Johannes, Kraemer, Thomas, Marquardt, Tobias, Mondritzki, Thomas, Nagelschmitz, Johannes, Nikkho, Sylvia M, Pires, Philippe V, Tinel, Hanna, Weimann, Gerrit, Wunder, Frank, Sandner, Peter, Schuhmacher, Joachim, Stasch, Johannes-Peter, Truebel, Hubert K F

“…Oxidative stress associated with severe cardiopulmonary diseases leads to impairment in the nitric oxide/soluble guanylate cyclase signaling pathway, shifting…”
Get full text

Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative—Group 3 Pulmonary Hypertension by Nathan, Steven D., Fernandes, Peter, Psotka, Mitchell, Vitulo, Patrizio, Piccari, Lucilla, Antoniou, Katerina, Nikkho, Sylvia M., Stockbridge, Norman

“…Pulmonary hypertension (PH) associated with interstitial lung disease (ILD) is an attractive target for clinical trials of PH medications. There are many…”
Get full text

Pathogenesis, clinical features, and phenotypes of pulmonary hypertension associated with interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative - Group 3 Pulmonary Hypertension by Piccari, Lucilla, Allwood, Brian, Antoniou, Katerina, Chung, Jonathan H, Hassoun, Paul M, Nikkho, Sylvia M, Saggar, Rajan, Shlobin, Oksana A, Vitulo, Patrizio, Nathan, Steven D, Wort, Stephen John

“…Pulmonary hypertension (PH) is a frequent complication of interstitial lung disease (ILD). Although PH has mostly been described in idiopathic pulmonary…”
Get full text

Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative—Group 3 pulmonary hypertension by Nikkho, Sylvia M., Richter, Manuel J., Shen, Eric, Abman, Steven H., Antoniou, Katerina, Chung, Jonathan, Fernandes, Peter, Hassoun, Paul, Lazarus, Howard M., Olschewski, Horst, Piccari, Lucilla, Psotka, Mitchell, Saggar, Rajan, Shlobin, Oksana A., Stockbridge, Norman, Vitulo, Patrizio, Vizza, Carmine Dario, Wort, Stephen J., Nathan, Steven D.

“…Pulmonary hypertension (PH) has been linked to worse outcomes in chronic lung diseases. The presence of PH in the setting of underlying Interstitial Lung…”
Get full text

Pulmonary hypertension in the setting of interstitial lung disease: Approach to management and treatment. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative—Group 3 Pulmonary Hypertension by Shlobin, Oksana A., Shen, Eric, Wort, Stephen J., Piccari, Lucilla, Scandurra, John A., Hassoun, Paul M., Nikkho, Sylvia M., Nathan, Steven D.

“…Pulmonary hypertension (PH) due to interstitial lung disease (ILD), a commonly encountered complication of fibrotic ILDs, is associated with significant…”
Get full text

Real‐world evidence to advance knowledge in pulmonary hypertension: Status, challenges, and opportunities. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative's Real‐world Evidence Working Group by Morland, Kellie, Gerges, Christian, Elwing, Jean, Visovatti, Scott H., Weatherald, Jason, Gillmeyer, Kari R., Sahay, Sandeep, Mathai, Stephen C., Boucly, Athénaïs, Williams, Paul G., Harikrishnan, Sivadasanpillai, Minty, Evan P., Hobohm, Lukas, Jose, Arun, Badagliacca, Roberto, Lau, Edmund M. T., Jing, Zhi‐Cheng, Vanderpool, Rebecca R., Fauvel, Charles, Leonidas Alves, Jose, Strange, Geoff, Pulido, Tomas, Qian, Junyan, Li, Mengtao, Mercurio, Valentina, Zelt, Jason G. E., Moles, Victor M., Cirulis, Meghan M., Nikkho, Sylvia M., Benza, Raymond L., Elliott, C. Gregory

“…This manuscript on real‐world evidence (RWE) in pulmonary hypertension (PH) incorporates the broad experience of members of the Pulmonary Vascular Research…”
Get full text

Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial by Simonneau, Gérald, Prof, D'Armini, Andrea M, Prof, Ghofrani, Hossein-Ardeschir, Prof, Grimminger, Friedrich, Prof, Jansa, Pavel, Prof, Kim, Nick H, Prof, Mayer, Eckhard, Prof, Pulido, Tomas, Prof, Wang, Chen, Prof, Colorado, Pablo, MD, Fritsch, Arno, PhD, Meier, Christian, MD, Nikkho, Sylvia, MD, Hoeper, Marius M, Prof

“…Summary Background Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare, debilitating, and life-threatening disease. We investigated associations…”
Get full text

Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial by Ghofrani, Hossein-Ardeschir, Prof, Grimminger, Friedrich, Prof, Grünig, Ekkehard, Prof, Huang, Yigao, Prof, Jansa, Pavel, Prof, Jing, Zhi-Cheng, Prof, Kilpatrick, David, Prof, Langleben, David, Prof, Rosenkranz, Stephan, Prof, Menezes, Flavia, MD, Fritsch, Arno, PhD, Nikkho, Sylvia, MD, Humbert, Marc, Prof

“…Summary Background Pulmonary arterial hypertension is a chronic disease associated with poor long-term outcomes. Identifying predictors of long-term outcome in…”
Get full text